Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HCV F1/F2 patients: treat now or continue to wait.

Liver international : official journal of the International Association for the Study of the Liver - 1 Feb 2014

Shiffman Mitchell L, Benhamou Yves

Abstract excerpt

The treatment of chronic HCV is evolving rapidly. In 2014, three new oral antiviral agents, simeprevir, faldeprevir and sofosbuvir will become available for patients with HCV genotype 1. These agents have far less side effects than the first generation protease inhibitors telaprevir and boceprevir. Treatment will therefore be easier for patients to tolerate but still require peginterferon and ribavirin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminoisobutyric Acids
Share to Heterocyclic Compounds, 3-Ring

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Oligopeptides

Share to Quinolines

Share to Simeprevir

Share to Sofosbuvir

Share to Thiazoles

Share to Uridine Monophosphate

Source

Identifiers

PMID: 24373082
DOI: 10.1111/liv.12408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

HCV F1/F2 patients: treat now or continue to wait.PMID 24373082Read ↗

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?Semantic proximity Read ↗

Optimal therapy of genotype-2 chronic hepatitis C: what's new?Semantic proximity Read ↗

Defining the possibilities: is short duration treatment of chronic hepatitis C genotype 1 with sofosbuvir-containing regimens likely to be as effective as current regimens?Semantic proximity Read ↗

LO3 : Safety and efficacy of the combination daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients from the french observational cohort ANRS CO22 hepather*Semantic proximity Read ↗

The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirinSemantic proximity Read ↗

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study.Semantic proximity Read ↗

Future perspectives: towards interferon-free regimens for HCV.Semantic proximity Read ↗

Boceprevir for Previously Treated Chronic HCV Genotype 1 InfectionSemantic proximity Read ↗

How to optimize current treatment of genotype 2 hepatitis C virus infection.Semantic proximity Read ↗

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.